|
Have you recently changed roles or institutions? Applied for new funding? If you have news to share, please update this Contact Form or send an email to Emily Kay. We look forward to hearing from you!
|
|
|
|
|
CURE Funding Deadlines
Research Supplements to Promote Diversity in Health-Related Research (DS) | PA-20-166 | Applications are due Oct. 1 - Dec. 31, 2020 and Feb. 1 - April 30, 2021
Kirschstein-NRSA Individual Predoctoral Fellowship to Promote Diversity in Health Related Research (F31-Diversity) | PA-19-196 | Applications are due Aug. 8, 2020, Dec. 8, 2020, and April 8, 2021
NCI Mentored Research Scientist Development Award to Promote Diversity (K01) | PAR-18-364 | PAR-18-365 | Applications are due June 12, 2020, Oct. 12, 2020 and Feb 12, 2021.
NCI Mentored Clinical Scientist Research Career Development Award to Promote Diversity (K08) | PAR-18-337 | PAR-18-336 | Applications are due June 12, 2020, Oct. 12, 2020 and Feb 12, 2021.
NCI Transition Career Development Award to Promote Diversity (K22) | PAR-18-366 | PAR-18-367 | Applications are due June 12 and Oct. 12, 2020
NCI Youth Enjoy Science Research Education Program (R25) | PAR-17-059 | Applications are due Sept. 25, 2020, Jan 25, 2021, and May 25, 2021.
Exploratory Grant Award to Promote Workforce Diversity in Basic Cancer Research (R21 Clinical Trial Not Allowed) | PAR-18-731 | Application are due June 19 and Nov. 19, 2020.
Basic Research in Cancer Health Disparities (R21/R01) | PAR-18-654 | PAR-18-655 | Application are due June 19 and Nov. 19, 2020.
Upcoming Non-CURE Funding Opportunities
Upcoming deadline! FOA for Building Population Health Research Capacity in the U.S. Affiliated Pacific Islands
Very little information regarding the specific health status of U.S.-Affiliated Pacific Islands (USAPI) populations is available. There is a critical need to collect basic epidemiological and health services data for USAPI populations residing in the region. NIMHD is supporting a new funding opportunity to build local organizations’ capacity to conduct ongoing population health research in the USAPI. The funding will support population health research projects that will provide novel data for USAPI populations and serve as the foundation for future research efforts. Click here to learn more.
Application Due Date: July 15, 2020, by 5:00 p.m. local time of applicant organization
Administrative Supplements to Support Cancer Disparity Collaborative Research | Due dates: September 10, 2020
Description: If you hold an active NCI-funded R01 (with at least 2 years of support remaining) and are interested in expanding your research to incorporate a cancer disparities research project, please consider submitting a proposal under FOA PA-18-842: Administrative Supplements to Support Cancer Disparity Collaborative Research. Please note that for this FOA, collaborative teams are required between a non-cancer disparities investigator (PI of the R01) and a collaborator who has minority health research or cancer disparities research expertise.
Modular R01s in Cancer Control and Population Sciences (R01 Clinical Trial Optional) | PAR-18-869 | Application due date November 6, 2020; March 8, 2021
Expiration Date: September 11, 2020
Exploratory/Developmental Grants Program for Basic Research in Cancer Health Disparities (R21 Clinical Trial Not Allowed) | PAR-18-655 | Applications are due Nov. 19, 2020.
The Sexual & Gender Minority Research Office (SGMRO) is pleased to announce the publication of a Notice of Special Interest (NOSI) regarding Administrative Supplements for Research on Sexual and Gender Minority (SGM) Populations (NOT-OD-20-032). Application Due Dates January 25, 2021 for FY 2021, by 5:00 PM local time of applicant organization.
Age-related Microbiota Changes and their Implications in Chronic Disease Prevention, Treatment and Progression (R01/R21 Clinical Trial Optional) | PA-18-738 | PA-18-739 | Application Due: Standard dates apply.
Expiration Date: May 8, 2021
Administrative Supplements to Promote Diversity in Research and Development Small Businesses-SBIR/STTR (Admin Supp Clinical Trial Not Allowed) | PA-18-837 | Expiration date: Sept. 5, 2021
NCI SBIR Administrative Supplements for Activities to Accelerate the Development and Commercialization of Cancer-Related Innovations | NOT-CA-20-012 | Expiration date: March 18, 2022
Mechanisms of Disparities in Chronic Liver Diseases and Cancer (R01/R21 Clinical Trials Not Allowed) | PAR-20-088 | PAR-20-081 | Expiration date: April 02, 2022
NCI's Healthcare Delivery Research Program (HDRP) Funding Opportunities
Feasibility and Planning Studies for Development of Specialized Programs of Research Excellence (SPOREs) to Investigate Cancer Health Disparities (P20, Clinical Trials Optional) | Application are due J October 18, 2020 | RFA-CA-19-034
Multilevel Interventions in Cancer Care Delivery: Follow-up to Abnormal Screening Tests (R01 Clinical Trial Optional) | PA-17-495 | Standard dates apply. Expiration date January 8, 2021.
Mechanisms of Disparities in Etiology and Outcomes of Lung Cancer in the U.S.: The Role of Risk and Protective Factors (R21/R01 Clinical Trial Not Allowed) | Applications are due March 4, 2021 | PAR-19-019 | PAR-19-018
Purpose: The purpose of this initiative is to promote multidisciplinary research to understand the underlying causal factors and mechanisms that result in lung cancer disparities in U.S. health disparity populations.
Co-infection and Cancer (R01/R21 Clinical Trial Not Allowed) | PAR-20-062 | PAR-20-061 | Standard dates apply
The purpose of this Funding Opportunity Announcement (FOA) is to enhance mechanistic and epidemiologic investigations addressing the roles of co-infection.
New Funding Opportunities
New! Upcoming Funding Opportunity Announcement: Community Interventions to Address the Consequences of the COVID-19 Pandemic for Health Disparity and Vulnerable Populations (R01 - Clinical Trial Optional)
NIMHD is partnering with other Institutes and Centers at the National Institute of Health to support an upcoming funding opportunity announcement (FOA): NOT-MD-20-023 Community Interventions to Address the Consequences of the COVID-19 Pandemic for Health Disparity and Vulnerable Populations (R01 - Clinical Trial Optional).Expected application due date: July 2020. For inquiries related to NIMHD’s scientific and research involvement concerning this FOA, contact Dr. Jennifer Alvidrez, at jennifer.alvidrez@nih.gov.
New! Funding Opportunity Announcements: The Rapid Acceleration of Diagnostics for Underserved Populations (RADx-UP) Initiative
NIH has issued a Notice of Intent to Publish (NOITP) four Funding Opportunity Announcements (FOAs) as part of Rapid Acceleration of Diagnostics for Underserved Populations (RADx-UP), a $500 million initiative to reduce COVID-19 associated morbidity and mortality disparities for vulnerable and underserved populations that are disproportionately affected by COVID-19.
As part of the RADx-UP initiative, NIH has released four funding opportunities ( https://www.nih.gov/research-training/medical-research-initiatives/radx/funding) to solicit community-engaged research on COVID-19 testing among underserved and/or vulnerable populations to both understand and close the disparity gap. Applications for this first phase will be accepted through August 2020 for FY20 funding. These funding opportunities include:
- NOT-OD-20-121: Emergency competitive revision applications to existing awards for large consortia, multi-site trials, centers and other current networks that have adequate capacity, infrastructure, and established community-engaged relationships to support large-scale testing interventions or have the capacity to ramp up quickly to reach underserved or vulnerable populations.
- NOT-OD-20-121:Complementary emergency competitive revision opportunity which shifts eligibility to collaborative and individual research awards, generally focused on smaller underserved or vulnerable populations.
- NOT-OD-20-119: Emergency competitive revisions to solicit research to understand the social, ethical, and behavioral implications (SEBI) of COVID-19 testing in these populations.
- RFA-OD-20-013: A new Coordination and Data Collection Center (CDCC) award (U24), a key component of the consortium. The CDCC will serve as a national resource, working with NIH scientific staff and consortium members to provide overarching support and guidance in the following four domains: (1) Administrative Operations and Logistics, (2) COVID-19 Testing Technology, (3) Community and Health System Engagement and (4) Data Collection, Integration and Sharing.
Notice of Special Interest (NOSI): NCI's Research Interests to Improve Interprofessional Teamwork and Coordination During Cancer Diagnosis and Treatment | NOT-CA-19-059
Contact: Sallie Weaver Application Due Date: This NOSI applies to due dates on or after September 25, 2019 through January 8, 2022. Applications related to this NOSI may be submitted using the following funding opportunity announcements or future reissuances: PAR-18-869, PAR-18-559, PA-19-056, PAR-18-290 An informational webinar is being planned. Please check our website for updates.
Intervening with Cancer Caregivers to Improve Patient Health Outcomes and Optimize Health Care Utilization | PAR-19-352 (R01), PAR-19-355 (R21) | Expiration Date: September 8, 2022
Contact: Michelle Mollica
Linking the Provider Recommendation to Adolescent HPV Vaccine Uptake | PAR-19-360 (R01), PAR-19-358 (R21), PAR-19-359 (R03) | Expiration Date: September 8, 2022 (R01 and R21); July 17, 2022 (R03)
Contact: Sarah Kobrin
Dissemination and Implementation Research in Health | PAR-19-274 (R01), PAR-19-275 (R21), PAR-19-276 (R03) | Expiration Date: May 8, 2022
Contact: Gila Neta, Wynne E. Norton, and David Chambers (from the DCCPS Implementation Science Team)
Funding Opportunity Announcement for Dissemination and Implementation Research in Health (R01/R21/R03) The purpose of this Funding Opportunity Announcement (FOA) is to support innovative approaches to identifying, developing, testing, evaluating and/or refining strategies to disseminate and implement evidence-based practices
Funding Opportunity Announcement Linking the Provider Recommendation to Adolescent HPV Vaccine Uptake (R01/R03/R21) Application Due Dates:
Other Funding Opportunities
Upcoming deadline! Notice of Intent to Publish a Funding Opportunity Announcement for Strengthening Institutional Capacity to Conduct Global Cancer Research (D43) | Application Due Date: June 30, 2020
The NCI intends to publish a FOA inviting applications from U.S.-based cancer-research intensive institutions who propose research training programs working in collaboration with a low-and middle-income country (LMIC) institution to strengthen capacity to conduct global research. NOT-CA-20-015
Mechanisms and Consequences of Sleep Disparities in the U.S. (R01 - Clinical Trial Not Allowed) | PAR-20-164 | Application Due Dates: July 14, 2020, July 14, 2021, July 14, 2022
Using Information Technology to Support Systematic Screening and Treatment of Depression in Oncology Practices (R01 Clinical Trial Optional) | PAR-18-493 | PAR-18-492 | Expiration date: May 8, 2021
Notice of Special Interest: Competitive and Administrative Supplements for the Impact of COVID-19 Outbreak on Minority Health and Health Disparities | NOT-MD-20-019 | Applications accepted on a rolling basis | Expiration date: May 1, 2021
Increasing Uptake of Evidence-Based Screening in Diverse Adult Populations (R01 Clinical Trial Optional) | PA-18-932 | Expiration date: January 08, 2022
NIMHD Exploratory/Developmental Research Grant Program (R21 - Clinical Trial Optional) | PAR-20-150 | Standard dates apply | Expiration date: May 8, 2023
Additional Resources
Standard Application Deadlines: For more on standard applications deadlines visit: https://grants.nih.gov/grants/how-to-apply-application-guide/due-dates-and-submission-policies/due-dates.htm Program staff are available to answer questions. Contact information and funding resources are available online.
Sample Grant Applications: The National Cancer Institute (NCI) frequently receives questions from investigators for examples of successfully funded grant applications. Several investigators and their organizations agreed to let the Division of Cancer Control & Population Sciences (DCCPS) programs post excerpts of their grant applications online.
|
|
Upcoming webinar! Implementation Science Webinar | Monday, June 29th from 3-4 PM EST
GMaP Region 4 is hosting a webinar about NCI Implementation Science Programs, Funding Opportunities, and Researcher Experiences. To join this webinar, please register here.
AACR Virtual Meeting: COVID-19 and Cancer | July 20-22, 2020
This meeting will focus on the presentation of emerging data in basic, clinical, and epidemiologic research related to COVID-19 and cancer. COVID-19 has encouraged innovation by cancer investigators and physician-scientists to address this pandemic, including the development of new diagnostic assays and new virus-targeted drugs; testing of next-generation vaccines; repurposing of oncology drugs to treat COVID-19 patients; and new approaches to patient care. AACR look forward to your attendance in this new initiative. Click here to learn more.
SUBMIT AN ABSTRACT! The Science of Cancer Health Disparities in Racial/Ethnic Minorities and the Medically Underserved | Oct. 2-5, 2020 | Miami, FL
Submit an abstract for the 13th AACR Conference on The Science of Cancer Health Disparities by July 17 for the opportunity to present your work to the top cancer disparities researchers. Highly-rated abstracts may be selected for short-talk oral presentations. To learn more, click here.
 |
|
|
NCI Cancer Prevention Fellowship Program | Applications close August 17, 2020
Be a part of the program that supports postdoctoral research and professional development training, plus offers:
- Competitive stipends, relocation expenses, health insurance benefits, and travel allowances
- Support for up to four years
- Opportunity to earn your MPH, sponsored by NCI
- Research opportunities with experienced NCI mentors
A cohort of fellows spanning STEM and other fields. Applications now open!
|
|
|
Scientific Positions at NIH
As the steward of medical and behavioral research for the Nation, the NIH scientific community encompasses diverse biomedical professionals involved in direct patient care activities, research, and/or scientific administrative roles. Scientific positions at the NIH include nurse researcher, physician-scientist, clinical and basic researchers, and data scientists. Additionally, the NIH supports the next generation of scientists, funding thousands of graduate students and postdoctoral fellows across the United States. Please learn more here.
More Career Opportunities & Resources
|
|
|
Resources & Tools
Guidance and Resources for Applicants
- Coronavirus 2019 (COVID-19) Information for Applicants and Recipients
- Flexibilities Available to Applicants and Recipients of Federal Financial Assistance Affected by COVID-19 - NOT-OD-20-086
- General Frequently Asked Questions (FAQs) - Proposal Submission and Award Management Related to COVID-19 - NOT-OD-20-083
- NIH Late Application Policy Due to Public Health Emergency for United States for 2019 Novel Coronavirus (COVID-19) - NOT-OD-20-091
Visit the GMaP Group for additional tools and resources for researchers, such as links to biospecimens, biorepositories, and statistician tools!
News
The National Institutes of Health and the Foundation for the NIH (FNIH) are bringing together more than a dozen leading biopharmaceutical companies, the Health and Human Services Office of the Assistant Secretary for Preparedness and Response, the Centers for Disease Control and Prevention, the U.S. Food and Drug Administration and the European Medicines Agency to develop an international strategy for a coordinated research response to the COVID-19 pandemic. The planned Accelerating COVID-19 Therapeutic Interventions and Vaccines (ACTIV) partnership will develop a collaborative framework for prioritizing vaccine and drug candidates, streamlining clinical trials, coordinating regulatory processes and/or leveraging assets among all partners to rapidly respond to the COVID-19 and future pandemics.
Episode 10: Ned Sharpless on COVID-19 Antibody Testing
Francis Collins: Home Edition, May 29, 2020
NIH Director Dr. Francis Collins and National Cancer Institute Director Dr. Ned Sharpless discuss the difference between viral and antibody testing, what antibodies tell us about the disease, why antibody tests alone are not suitable for informing back to workplace efforts, the status of antibody tests, and NCI’s role working with the U.S. Food and Drug Administration to test and validate SARS-CoV-2 antibody tests.
Sacituzumab Govitecan Approved for Metastatic Triple-Negative Breast Cancer
NCI Cancer Currents Blog, May 28, 2020
The approval covers the use of sacituzumab govitecan in adults with triple-negative breast cancer that has spread, or metastasized, to other parts of the body. Approval based on manufacturer-sponsored trial in which 1/3 of the 108 patients had a tumor response i.e., tumor shrank by 30+%, and the response lasted an avg. of 7.7 months.
Additional news and a list of newsletters are available on our news page.
|
|
Screen to Save
This CRCHD initiative aims to increase colorectal screening rates among racial and ethnic minority communities nationwide. Working through the NCI-supported National Outreach Network, community health educators (CHEs) will provide culturally tailored, evidence-based colorectal cancer information, education, and screening resources within underserved populations.
Visit Screen to Save to learn more about this initiative.
|
|
|
Additional news and a list of newsletters are available on our news page.
|
|
|
|
